ProAxis expects increased sales of its antibody drug ProteaseTag

Ikaba Koyi WebFG News | 21 Nov, 2017 16:46 - Updated: 16:46 | | |

drugo, drugs, medical, health

NetScientific

72.50

17:17 15/12/17
-0.00%
-0.00
  • 10,768.56
  • 0.27%28.55
  • Max: 10,768.56
  • Min: 10,673.76
  • Volume: 0
  • MM 200 : n/a
17:25 15/12/17
  • 1,014.92
  • 0.01%0.13
  • Max: 1,016.55
  • Min: 1,013.24
  • Volume: 0
  • MM 200 : n/a
17:25 15/12/17
  • 0.00
  • 0.00%0.00
  • Max: n/a
  • Min: n/a
  • Volume: n/a
  • MM 200 : n/a
17:17 25/09/06

NetScientific, the transatlantic healthcare IP commercialisation group, has today announced that ProAxsis, its portfolio company in which it holds a 57% stake, is forecasting higher direct sales of its ProteaseTag Active Neutrophil Elastase Immunoassay.

ProAxsis said it expected its NEIA sales to increase three-fold in the second half of 2017 versus the first six months of the year with total revenue expected to surpass £1m in 2018.

Commenting on the news, Francois Martelet, chief executive officer of NetScientific and Chairman of ProAxsis, said: "We are pleased to see signs of rapid market adoption of the CE marked NEIA test which uses ProAxsis' market leading ProteaseTag® technology. We are especially encouraged to see the acceleration of sales through a combination of repeat orders and new customers from leading research institutions across Europe and the US. We expect 2018 to be a pivotal year for ProAxsis with further planned product launches and potential industry partnerships as value inflection points."

More news

15 Dec London close: Footsie gains as pound drops, Wall Street hits fresh highs

The top flight index recovered some ground on Friday, but mostly on account of weakness in Sterling after German Chancellor Angela Merkel reportedly echoed other European Union officials, saying "the most difficult phase is ahead of us".

15 Dec Week ahead: US data, Catalan elections in focus

The focus in the coming week will continue to be on the ebb and flow of data out of the US, including Republicans' progress on securing passage of their tax cuts.

15 Dec US open: Stocks jump as Republicans move to secure passage of tax cuts

Wall Street is heading higher again on Friday amid news that Republicans were tweaking their proposed tax cuts in order to secure prompt passage of the US tax bill.

15 Dec Airbus chief executive to step down in board shake-up

The chief executive of French planemaker Airbus will step down from his position in 2019 as the company announced a major shake-up of its management team.

15 Dec FTSE 250 movers: TalkTalk rises but Serco gives back gains

London’s FTSE 250 was up 0.1% to 20,023.23 in afternoon trade on Friday as the Christmas lull kicked in.

15 Dec US industrial production rises slightly less than expected in November

Industrial production in the States rose slightly less quickly than expected last month, despite higher output of business equipment and materials.

15 Dec Strategic Minerals renegotiates acquisition of Leigh Creek Copper Mine

Diversified mineral production and development company Strategic Minerals announced on Friday that, after the successful completion of technical and financial due diligence on the Leigh Creek Copper Mine company, it has agreed to continue with the acquisition on renegotiated terms.

15 Dec FTSE 100 movers: Sky jumps but retailers retreat on H&M sales

London’s FTSE 100 was up 0.3% to 7,469.23 in quiet afternoon trade on Friday.

15 Dec Gfinity partners with Microsoft for next Halo World Championship

International esports entertainment group Gfinity has been named as a preferred event partner to Microsoft for the forthcoming ‘Halo World Championship 2018’ for the next season, it announced on Friday.

15 Dec Hutchison Chi-Med begins fruquintinib trial in US

Hutchison China MediTech, known as Chi-Med, has initiated the United States Phase I bridging clinical trial of fruquintinib, it announced on Friday.